Novo Nordisk's GLP-1 pill momentum faces pricing test, says leading bank Proactive uses images sourced from Shutterstock Novo Nordisk (NYSE:NVO) reports first-quarter 2026 results on 6 May, with UBS flagging that the results will provide the first meaningful look at the company's economics at new, lower price points for its GLP-1 (glucagon-like peptide-1) obesity and diabetes drugs. The Danish pharmaceutical company has shed 27% of its market value year to date, hit by full-year 2026 guidance that came in ...